AFP and neoplasm: Their ANN integrated a combination of clinical and biological features—such as tumor size, AFP level, and immune parameters like CD4 T-cell count—and outperformed conventional systems (e.g., BCLC, TNM, CLIP), achieving an AUROC of 0.866 for PFS prediction.